Free Trial
→ This little-known fund tracks gold and pays out weekly (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
$54.65
+0.2%		$54.50
$37.28
▼
$57.35
$4.50B-0.41.86 million shs15.31 million shs
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$24.21
$22.99
$21.43
▼
$50.79
$788.28M0.74686,800 shs775,375 shs
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
▼
$31.25
$8.32B1.188.78 million shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.00%0.00%0.00%0.00%+1.13%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
0.00%+1.72%+9.60%-10.99%-42.77%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
$54.65
+0.2%		$54.50
$37.28
▼
$57.35
$4.50B-0.41.86 million shs15.31 million shs
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$24.21
$22.99
$21.43
▼
$50.79
$788.28M0.74686,800 shs775,375 shs
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
▼
$31.25
$8.32B1.188.78 million shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.00%0.00%0.00%0.00%+1.13%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
0.00%+1.72%+9.60%-10.99%-42.77%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.00
BuyN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.80
Moderate Buy$44.8885.36% Upside
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest COLL, IMGN, and AKRO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/6/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$35.00
11/6/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetNeutral$43.00 ➝ $28.00
11/5/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$46.00 ➝ $44.00
10/15/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong Sell ➝ Strong-Buy
10/6/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold ➝ Strong Sell
9/23/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$50.00
9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$45.00
9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$58.00 ➝ $49.00
9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$58.00 ➝ $49.00
9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$45.00
(Data available from 11/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/A$10.75 per shareN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$780.57M1.01$15.23 per share1.59$9.54 per share2.54
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$287.61M28.91N/AN/A$0.71 per share43.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$252.06M-$1.94N/AN/AN/AN/A-15.86%-14.78%N/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$62.87M$1.0024.214.110.754.68%85.14%13.80%N/A
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/A

Latest COLL, IMGN, and AKRO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.86$1.96+$0.10$0.60$216.03 million$216.34 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/A
15.84
15.83
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.44
1.01
0.87
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.13
5.70
5.65

Institutional Ownership

CompanyInstitutional Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/A
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
90.50%

Insider Ownership

CompanyInsider Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
7.07%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
1.85%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
5.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3082.32 million76.50 millionOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
42332.56 million31.95 millionOptionable
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
277266.26 million252.76 millionOptionable

Recent News About These Companies

MindWalk Showcases High-Speed, Lower-Cost LensAI Immunogenicity Screening on AMD-Powered AWS Cloud
October 21, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mindwalk-showcases-high-speed-lower-cost-lensai-immunogenicity-screening-on-amd-powered-aws-cloud?utm_source=marketbeat.com&utm_medium=referral
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
July 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20221228005248/en/ImmunoGen-Announces-Susan-Altschuller-on-FMLA-Leave-Interim-CFO-Appointed
GridAI Technologies completes ImmunogenX ownership rescission transaction
January 7, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/gridai-technologies-completes-immunogenx-ownership-rescission-transaction?utm_source=marketbeat.com&utm_medium=referral
Entero Therapeutics Amends Rescission Agreement with ImmunogenX
July 16, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/entero-therapeutics-amends-rescission-agreement-with-immunogenx?utm_source=marketbeat.com&utm_medium=referral
BPDCN Market Set for Robust Growth Through 2032 Driven by Targeted Therapies and Rising Disease Awareness | DelveInsight
April 15, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GetNews/31887953/bpdcn-market-set-for-robust-growth-through-2032-driven-by-targeted-therapies-and-rising-disease-awareness-delveinsight/
Federal Circuit Affirms ImmunoGen Patent Obviousness
March 12, 2025  |  natlawreview.comN
Federal Circuit Affirms District Court’s Obviousness Judgment on ImmunoGen Patent Application
March 12, 2025  |  natlawreview.comN
AbbVie's SWOT analysis: stock outlook strong despite humira loss
February 4, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/abbvies-swot-analysis-stock-outlook-strong-despite-humira-loss/ar-AA1ymNyM
Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits Research
January 22, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/01/22/3013689/0/en/antibody-drug-conjugates-market-size-is-expected-to-reach-usd-25-38-billion-by-2033-growing-at-a-cagr-of-8-84-straits-research.html
Pivekimab sunirine by ImmunoGen for Blood Cancer: Likelihood of Approval
December 30, 2024  |  pharmaceutical-technology.comP
AbbVie bags EU nod for key drug from ImmunoGen takeover
November 18, 2024  |  pharmaphorum.comP
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
November 5, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/puretech-founded-entity-seaport-therapeutics-120500863.html
Seaport Therapeutics Names Lauren White as Chief Financial Officer
November 5, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/seaport-therapeutics-names-lauren-white-120000384.html
Artisan International Small-Mid Instl
October 25, 2024  |  morningstar.comM
Artisan International Small-Mid Advisor
October 25, 2024  |  morningstar.comM
Lilly revives ImmunoGen ADC pact with new $1.7bn deal
October 12, 2024  |  pharmaphorum.comP
Which Is a Better Investment, ImmunoGen, Inc. or Morphosys Ag (ADR) Stock?
August 7, 2024  |  aaii.comA
ImmunoGen ELAHERE wins accelerated FDA approval for ovarian cancer
July 28, 2024  |  pharmaphorum.comP
In Oncology, Antibody-Drug Conjugates Are a Hot Ticket
May 14, 2024  |  managedhealthcareexecutive.comM
AbbVie concludes acquisition of ImmunoGen
February 14, 2024  |  medicaldialogues.inM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Whirlpool logo overlaid on a kitchen with stainless steel refrigerator, range hood, and a laundry area with washer and dryer.
Whirlpool's Stock Collapse Raises a Bigger Question About Its Recovery Potential
By Thomas Hughes | October 27, 2026
Albertsons logo overlaid on a grocery store interior with produce displays, refrigerated cases, and shopping carts.
Albertsons Is Betting on a Turnaround—But Will It Pay Off?
By Thomas Hughes | October 14, 2026
Split image of industrial garment facilities with Cintas and UniFirst logos over racks of uniforms on conveyor systems.
FTC Puts A Wrinkle In the Cintas and UniFirst Merger
By Jeffrey Neal Johnson | October 30, 2026
Visa logo displayed over a retail store checkout counter with a payment terminal and shopping bags.
Visa's Toll Booth Keeps Collecting, But the Price Is Rising
By Chris Markoch | October 29, 2026
Atlassian logo in modern office with digital workflow icons streaming outward.
Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
By Leo Miller | November 9, 2026
Akero Therapeutics stock logo

Akero Therapeutics NASDAQ:AKRO

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$24.21 0.00 (0.00%)
Closing price 11/6/2026 04:00 PM Eastern
Extended Trading
$24.36 +0.15 (+0.62%)
As of 07:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

ImmunoGen stock logo

ImmunoGen NASDAQ:IMGN

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas